Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1965 2
1966 4
1967 5
1968 3
1969 1
1970 2
1971 4
1972 3
1975 3
1976 2
1977 2
1978 3
1979 1
1981 1
1982 1
1984 5
1985 3
1986 3
1987 2
1989 2
1991 2
1992 1
1993 1
1994 4
1995 2
1997 2
1998 3
1999 3
2000 2
2001 1
2002 1
2004 7
2005 3
2006 5
2007 7
2008 4
2009 7
2010 12
2011 6
2012 12
2013 14
2014 23
2015 22
2016 15
2017 13
2018 26
2019 21
2020 18
2021 11
Text availability
Article attribute
Article type
Publication date

Search Results

272 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators. Hamada H, et al. Among authors: hanaoka h. Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Lancet. 2019. PMID: 30853151 Clinical Trial.
Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Mitsuhashi A, Kawasaki Y, Hori M, Fujiwara T, Hanaoka H, Shozu M. Mitsuhashi A, et al. Among authors: hanaoka h. BMJ Open. 2020 Feb 28;10(2):e035416. doi: 10.1136/bmjopen-2019-035416. BMJ Open. 2020. PMID: 32114477 Free PMC article. Clinical Trial.
Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy.
Sato K, Ando K, Okuyama S, Moriguchi S, Ogura T, Totoki S, Hanaoka H, Nagaya T, Kokawa R, Takakura H, Nishimura M, Hasegawa Y, Choyke PL, Ogawa M, Kobayashi H. Sato K, et al. Among authors: hanaoka h. ACS Cent Sci. 2018 Nov 28;4(11):1559-1569. doi: 10.1021/acscentsci.8b00565. Epub 2018 Nov 6. ACS Cent Sci. 2018. PMID: 30555909 Free PMC article.
Interferon α-targeted therapy.
Hanaoka H, Takeuchi T. Hanaoka H, et al. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(4):181-8. doi: 10.2177/jsci.36.181. Nihon Rinsho Meneki Gakkai Kaishi. 2013. PMID: 23994795 Review. English, Japanese.
Low-dose rituximab as induction therapy for ANCA-associated vasculitis.
Takakuwa Y, Hanaoka H, Kiyokawa T, Iida H, Fujimoto H, Yamasaki Y, Yamada H, Kawahata K. Takakuwa Y, et al. Among authors: hanaoka h. Clin Rheumatol. 2019 Apr;38(4):1217-1223. doi: 10.1007/s10067-019-04443-2. Epub 2019 Jan 25. Clin Rheumatol. 2019. PMID: 30680533
Sivelestat sodium hydrate treatment for refractory Kawasaki disease.
Ebata R, Yasukawa K, Nagai K, Saito Y, Higashi K, Homma J, Takada N, Takechi F, Saito N, Kobayashi H, Okunushi K, Hamada H, Kohno Y, Hanaoka H, Shimojo N. Ebata R, et al. Among authors: hanaoka h. Pediatr Int. 2019 May;61(5):438-443. doi: 10.1111/ped.13851. Epub 2019 May 17. Pediatr Int. 2019. PMID: 30916859 Clinical Trial.
272 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page